New EU Filings Include First Self-Administered Treatment For Myasthenia Gravis

 
• By Neena Brizmohun

UCB’s zilucoplan for treating gMG is among the latest new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.

Close up shot of team of professionals meeting with digital tablet and charts. Business people discussing financial plan. Human hands pointing at grap
The EMA has started reviewing a new batch of drug marketing applications • Source: Alamy

More from Product Reviews

More from Pink Sheet